Core Viewpoint - The company, Duori Pharmaceutical (301075.SZ), has announced a plan to repurchase shares through a concentrated bidding method, which will be followed by a reduction in shareholding [1] Group 1: Share Repurchase Plan - The board of directors has approved a proposal regarding the share repurchase and subsequent reduction plan [1] - The company intends to sell back the repurchased shares within a period of six months, starting from 15 trading days after the announcement [1] - The maximum number of shares to be sold is 1.0445 million, which represents 1.31% of the company's total share capital [1] Group 2: Sale Conditions - The sale price of the repurchased shares will be determined based on the secondary market price [1] - The implementation period for the sale is set from January 14, 2026, to July 13, 2026, excluding any periods prohibited by the China Securities Regulatory Commission and the Shenzhen Stock Exchange [1]
多瑞医药：拟出售不超104.45万股已回购股份